Biogen Inc. and Neomorph Inc. have entered into a partnership to develop molecular glue degraders for Alzheimer’s disease and other neurologic conditions. Biogen aims to use Neomorph’s discovery platform to accelerate the identification and validation of small molecule degraders that can remove harmful proteins associated with disease pathology. The partnership will focus on identifying, validating, and optimizing the glue degraders for high-priority targets, with Biogen responsible for advancing viable candidates for clinical development. Neomorph stands to receive up to $1.45 billion in milestone payments, as well as future royalties, based on the success of the collaboration.
Source link
Biogen, Neomorph partner to advance molecular glue degraders for neurologic conditions
